Showing 1 - 6 results of 6 for search 'Kenneth H Yu', query time: 0.04s Refine Results
  1. 1
    An Experimental Investigation of Low-Frequency Active Excitation in Scramjet Combustor Using a Micro-Pulse Detonation Engine

    An Experimental Investigation of Low-Frequency Active Excitation in Scramjet Combustor Using a Micro-Pulse Detonation Engine by Keon-Hyeong Lee, Min-Su Kim, Jeong-Yeol Choi, Kenneth H. Yu

    Published 2024-07-01
    Get full text
    Article
  2. 2
    Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma

    Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma by Kenneth H. Yu, Paul Cockrum, Andy Surinach, Neil Lamarre, Shu Wang, Eileen M. O'Reilly

    Published 2023-04-01
    Get full text
    Article
  3. 3
    Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes

    Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes by Eileen M. O'Reilly, Paul Cockrum, Andy Surinach, Zheng Wu, Allison Dillon, Kenneth H. Yu

    Published 2020-11-01
    Get full text
    Article
  4. 4
    Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma.

    Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma. by Louise M Fanchon, James Russell, Nagavarakishore Pillarsetty, Isabella O'Donoghue, Kishore Gangangari, Kenneth H Yu, John L Humm

    Published 2020-01-01
    Get full text
    Article
  5. 5
    Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan

    Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan by Kenneth H. Yu, Andrew E. Hendifar, Olatunji B. Alese, Amber Draper, Maen Abdelrahim, Ethan Burns, Gazala Khan, Paul Cockrum, Rachel H. Bhak, Catherine Nguyen, Maral DerSarkissian, Mei Sheng Duh, Nathan Bahary

    Published 2021-07-01
    Get full text
    Article
  6. 6
    Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer

    Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer by Suhasini Joshi, Erica DaGama Gomes, Tai Wang, Adriana Corben, Tony Taldone, Srinivasa Gandu, Chao Xu, Sahil Sharma, Salma Buddaseth, Pengrong Yan, Lon Yin L. Chan, Askan Gokce, Vinagolu K. Rajasekhar, Lisa Shrestha, Palak Panchal, Justina Almodovar, Chander S. Digwal, Anna Rodina, Swathi Merugu, NagaVaraKishore Pillarsetty, Vlad Miclea, Radu I. Peter, Wanyan Wang, Stephen D. Ginsberg, Laura Tang, Marissa Mattar, Elisa de Stanchina, Kenneth H. Yu, Maeve Lowery, Olivera Grbovic-Huezo, Eileen M. O’Reilly, Yelena Janjigian, John H. Healey, William R. Jarnagin, Peter J. Allen, Chris Sander, Hediye Erdjument-Bromage, Thomas A. Neubert, Steven D. Leach, Gabriela Chiosis

    Published 2021-11-01
    Get full text
    Article

Search Tools: